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Summary 
CD97 is an activation-induced antigen on leukocytes with a seven-span transmembrane  (7-TM) 
region homologous to the secretin receptor superfamily. However, in contrast to this group of 
peptide  hormone receptors,  CD97  has an extended  extracellular  region with  three EGF  do- 
mains at the NH2 terminus,  two of them with a calcium binding site.  By demonstrating that 
lymphocytes and erythrocytes specifically adhere to CD97-transfected COS cells we here show 
that  CD97  in  parallel  with  its  molecular  evolution  has  acquired  the  ability  to  bind  cellular 
ligands. A  mAb selected on its capacity to block the adhesion between CD97 transfectants and 
red cells was found to be directed to the NHz-terminal short consensus repeat (SCR) of decay 
accelerating factor (DAF, CD55),  a regulatory protein of the complement cascade. The speci- 
ficity of the interaction of CD97 with CD55 was established by the observation that erythro- 
cytes  that  lack  CD55,  obtained  from  patients  with  paroxysmal  nocturnal  hemoglobinuria 
(PNH) or the CD55- phenotype Inab, failed to adhere to CD97 transfectants.  This is the first 
demonstration of a cellular ligand for a 7-TM receptor. 
C 
D97 is an antigen which becomes immediately upreg- 
ulated  on most leukocytes during activation  (1).  We 
recently  identified  CD97  as  a  7-TM  molecule  whose 
membrane-spanning  region is  homologous to the  secretin 
receptor superfamily (2).  CD97 is different from this group 
of mammalian and insect peptide hormone receptors (3,  4), 
in  that  it  has  an  extended  extracellular  region  with  three 
EGF domains at the NH 2 terminus. The finding of a highly 
similar architecture in EMR1  (5),  which possesses six EGF 
domains, and its probable murine homologue F4/80 (6) in- 
dicates  the  existence  of a  new  group  of 7-TM  receptors 
characterized by several  NH2-terminal  EGF  domains.  We 
have  demonstrated  that  this  new  type  of 7-TM  molecule 
has recently evolved by exon shuffling to the upstream re- 
gion of an ancestral gene from the secretin receptor super- 
family (7). 
All EGF domains in CD97 and EMR1, except the most 
NH2-terminal  ones,  possess  a  calcium  binding  site.  The 
Ca  2+  in this subgroup  of EGF domains  stabilizes  the  con- 
formation of the domain and can mediate contact to other 
proteins  (8).  The rather recent acquisition of EGF domains 
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raised the possibility that CD97, unlike  members from the 
secretin  receptor  supeffamily,  has  a  cellular  ligand  (2).  In 
this report evidence is provided that this assumption is valid 
since we show that CD97 specifically binds CD55  (or de- 
cay accelerating factor,  DAF),  a  GPI-linked molecule  ex- 
pressed on most leukocytes. 
Materials  and Methods 
Adhesion Assays.  Binding studies  were performed with COS 
cells three days after transient  transfection  with CD97 cDNA (2) 
using lipofectamine  (GIBCO  BILL,  Gaithersburg,  MD).  Typi- 
cally, 30% of COS cells expressed  CD97,  as determined by im- 
munoperoxidase staining  with  CD97  mAbs.  At day one,  COS 
cells were replated  into six-well  culture plates. Mock-transfection 
was performed by the same procedure, except that no cDNA was 
added. 
To  analyze  binding,  10  ￿  10  ~' PBL,  obtained  from human 
venous blood by isolation  on a Percoll density gradient followed 
by counterflow:centrifugal etutriation,  or 100 ￿  10  ~' erythrocytes 
were suspended in 1 ml DMEM and overlaid on the COS cells 
for 30 rain at 20~  Non-adhering cells were removed by gentle 
washing with PBS before examination by microscopy. 
For blocking experiments,  erythrocytes were labeled with SlCr 
according to  manufacturers  recommendations  (Amersham Co., 
Buckinghamshire,  UK).  Binding  assays were  performed  in  12- 
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moving non-adhering cells, the y  emission of well contents lysed 
with  1% Triton X-100 was determined. 
Generation of Monodonal Antibodies.  The  mAb  CLB-CD97L/1 
(lgG1) was produced by fusing mouse nweloma SP2/0 cells with 
spleen  cells  from  a  BALB/c  mouse  inmmnized  with  human 
erythrocytes. Hybridoma supernatants were screened for the ca- 
pacity to block the adhesion of erythrocytes to  COS  cells trans- 
fected with CD97 and replated into 96-well culture plates. 
Blocking of CLB-CD97L/1  by CD55 nkAbs was tested by in- 
cubation of PBL with IA10 for 20 rain before staining with bio- 
tinylated CLB-CD97L/1, followed by PE-streptavidin. Flow cy- 
tometric analysis was done  on  a  FACScan  |  (Becton Dickinson, 
Mountain View, CA). 
CLB-CD97/1  (IgG2a)  is a CD97 mAb that was obtained after 
fusion of spleen cells from a BALB/c mouse that had been immu- 
nized with  NIH-3T3  cells  stably expressing CD97  with  SP2/0 
cells.  CLB-CD97/1  inhibits binding of biotinylated BL-Ac/F2 
indicating that both mAbs are directed to the same CD97 epitope 
(data not shown). 
lmtmmoprecipitation.  Biochemical analyses were performed as 
described previously (9). Briefly, K562 cells were labeled with 125I 
(Amersham  Co.)  by  the  glucose/lactoperoxidase protocol  and 
lysed in  1% NP-40  buffer,  containing 10  mM  triethanolamine- 
HC1,  pH  7.8,  150  mM NaC1,  5 mM EDTA,  1 mM  PMSF, 20 
#,g/ml  ovomucoid trypsin inhibitor,  1 mM  Na-p-tosyl-l-lysine 
chloromethyl ketone, and 20  Izg/ml leupeptin. After centrifuga- 
tion, supernatants were precleared with mouse normal lg (last pre- 
clear is shown in the left lane) and incubated with CLB-CI)97L/1 
and  IA10,  a  CD55  mAb  derived from  the  Fifth  International 
Leucocyte Typing Workshop (10).  Inunune complexes were ad- 
sorbed onto protein A-Sepharose (Pharmacia, Uppsala, Sweden), 
eluted  under  reducing  conditions,  electrophoretically separated 
by 5-15'/, SDS-PAGE, and visualized by autoradiography. 
Studies with CD55-dqficiem Erythrofftes.  To  deplete CD55-posi- 
tive cells from erythrocytes of paroxysmal nocturnal hemoglobin- 
uria (PNH) patients, cells were incubated with saturating amounts 
of CLB-CD97L/I  before addition of anti-mouse IgG magnetic 
beads  (Dynal,  Oslo,  Norway)  and  immunomagnetic  selection. 
Expression of CD55  on  the  erythrocyte populations was  deter- 
mined by flow cytometry with CLB-CD97L/1  or a subclass con- 
trol  mAb.  The  Inab  phenoWpe  erythrocytes examined  in  this 
study are from a new, unpublished case of this extremely rare dis- 
order  (Dr.  G.  Daniels,  personal  conmmnication),  Binding  of 
erythrocytes to CD97-transfected COS cells was  analyzed as de- 
scribed above. 
Results  and Discussion 
CD97  Can Mediate Intercellular Adhesion.  We have pre- 
viously noticed that the structural features of CD97 suggest 
an adhesive function for its extracellular region (2).  Indeed, 
as shown  in Fig.  1,  PBL and erythrocytes adhered to COS 
cells  expressing CD97.  This  interaction  was  shown  to  be 
specific  since  pre-incubation  of  COS  cells  with  CI)97 
mAbs (either CLB-CD97/1  or BL-Ac/F2  [1])  completely 
abolished binding. 
CD55 Is a Ligand for CD97.  Once  the  binding studies 
had indicated that a ligand for CD97  is being expressed on 
erythrocytes, immunization  of mice  with  human  erythro- 
cytes combined with  standard  hybridoma  technology was 
used to  generate a  ligand-specific mAb.  One  mAb  (CLB- 
CD97L/1)  was  identified  that  blocked  the  adherence  of 
both erythrocytes and PBL to CD97-transfected COS cells. 
Biochemical  analysis  showed  that  this  mAb  recognizes  a 
70-kD protein (Fig. 2 A). Among antigens of this size stud- 
ied  during  the  Fifth  International  Leucocyte  Typing 
Workshop,  a  small number  was found  to be  expressed on 
both  erythrocytes and  lymphocytes  (10).  When  we  tested 
the  capacity  of mAbs  directed  against  these  antigens  to 
block  the  binding  of erythrocytes  to  CD97  transfectants, 
IA10,  a mAb recognizing CD55  (11)  turned out to be in- 
hibitory.  A  direct  comparison  of  CLB-CD97L/1  with 
IAI0  revealed  that  both  mAbs  immunoprecipitated  not 
only the same major protein of 70 kD  which characterizes 
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Figure  1.  Adherence of human PBL  (A) and 
erythrocytes (/3) to COS cells expressing CI)97. 
Both  B  and  T  lymphocytes adhere to  Cl)97- 
transfected COS  cells as revealed from experi- 
ments with  purified cells (data not shown). No 
binding is detectable m the presence of 5 ~g/ml 
of CI)97 mAbs CLB-C1)97/1  (shown) or BL- 
Ac/F2 (C), or when cells are overlaid on mock- 
transfected COS cells (D). Figure  2.  CLB-CD97L/1, a mAb generated  to the cellular ligand of 
CD97  is  specific  for CD55.  (A)  CLB-CD97L/1  and  the  CD55  mAb 
IA10  immunoprecipitate  the  same  major  protein  of 70  kD  from  the 
erythromyeloid  cell line K562.  Notably,  also a smaller band  at  140  kD 
representing  dimeric  CD55 (13) is detectable  in the CLB-CD97L/1 ina- 
munoprecipitate.  The position  of molecular  size markers in kD are indi- 
cated on the left. (B) The binding ofbiotinylated CLB-CD97L/1 to PBL 
(dashed  line) is blocked by the C1)55 mAb IA10 (solid line). 
the CD55  antigen  (12),  but also a  minor band  migrating at 
140  kD  which  represents  dimeric  CD55  (13)  (Fig.  2  A). 
Furthermore,  IA10  was  found  to  completely  block  the 
binding  of biotinylated  CLB-CD97L/1  to  PBL  (Fig.  2  B), 
indicating  that  the  mAb  generated  to  the  ligand  of CD97 
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Figure  3.  CD55 mAbs inhibit  the binding of erythrocytes  to CD97- 
transfected  COS cells. Adhesion  of S~Cr-labeled erythrocytes  to  CD97- 
transfected  COS cells was assessed in  the presence  of 5 p.g/ml of mAbs 
specific for CD97 (CLB-CD97/1), CD55 (CLB-CD97L/1, IA10, BRIC 
220,  230,  110, 216) or a mouse  IgG1  control mAb.  The CD55  mAbs 
used  are  directed  to  the  first (IA10,  BRIC220,  BRIC230),  second 
(BRIC110),  or third (BRIC216)  SCR domain (14). Results are expressed 
as the percent oferythrocyte binding,  relative to the amount bound in the 
absence  of mAbs. Data shown are mean  +  SD of duplicate  determina- 
tions in three independent experiments. 
Figure  4.  CD55-deficient  erythrocytes  are  not  able  to  adhere  to 
CD97-transfected  COS cells. (A) Erythrocytes from an PNH patient bind 
to CD97-transfected  COS cells (upper  right panel)  due to the presence  of 
non-afflicted  cells in this clonal disease (16, 17) (upper left panel). After re- 
moving  the  CD55-positive  erythrocytes  by  immunomagnetic  sorting 
(lower  left  panel),  adherence  was  completely  abolished  (lower  right panel). 
One representative  experiment  out of four is shown.  (B) The complete 
absence  of CD55  expression  in the Inab  phenotype  (18, 19)  (left panel) 
prevents  erythrocytes  from binding to CD97-transfected  COS cells (right 
panel). 
recognizes  the  same  epitope  as  IA10  that  has  been  previ- 
ously mapped to the first (of four)  SCR  of CD55  (14). 
CD55  is  a  GPI-anchored  molecule  expressed  by  all 
blood  cells and  cells in  contact with blood  and  tissue  fluid 
that  by  inhibiting  C3/C5  convertases  protects  them  from 
complement-mediated  damage  (12).  To  investigate  the 
specificity  of the  interaction  between  CD97  and  CD55,  a 
larger panel  of CD55  mAbs,  directed  against  distinct  SCR 
domains  within  the molecule,  was  tested in the  above  de- 
scribed  adherence  assay.  As  shown  in  Fig.  3,  inhibition  of 
erythrocyte  adhesion  to  CD97-transfected  COS  cells  be- 
tween 23 and 92% was observed. The finding that also mAbs 
mapping  to  the  second  (BRIC110)  and  third  (BRIC216) 
SCR  of CD55  are able to block binding suggests that these 
domains,  in addition  to the first SCR,  are involved in liga- 
tion of CD97.  The  ability to  dissociate  and prevent assem- 
bly of C3/C5  convertases  in both  the  classical and  alterna- 
tive pathway  of the complement cascade  has  recently been 
mapped  to the SCR  domains  two,  three and four (14,  15). 
The finding that  the first SCR  of CD55  is involved in ad- 
1187  Hamann et al.  Brief Definitive Report hesion  to  CD97  is the  first demonstration  of a  molecular 
function for this domain. 
CD55-deficient  Erythrocytes  Do  Not Bind to  CD97  Trans- 
fectants.  Further evidence that CD97  specifically interacts 
with CD55  came from observations that erythrocytes lack- 
ing CD55  expression fail to adhere to CD97  transfectants. 
First,  PNH  is  an  acquired  somatic  defect  in  GPI-anchor 
synthesis that leads to the absence of GPI-anchored mole- 
cules (16,  17).  Due to the clonal character of this hemato- 
poietic stem cell disorder, both CD55-positive and CD55- 
negative red cells circulate in the blood of afflicted patients. 
CD55-positive  erythrocytes  from  these  patients  have  re- 
tained the ability to bind CD97  transfectants (Fig. 4 A,  up- 
per panels).  However,  after  depletion  of  the  unaffected, 
CD55-expressing  erythrocytes,  a  complete  abrogation  of 
adherence  was  seen  (Fig.  4  A,  lower panels).  Second,  the 
Inab phenotype represents an inherited deficiency in CD55 
expression due  to truncative mutations in the CD55  gene 
(18,  19). Erythrocytes with this phenotype completely lacked 
the ability to bind COS cells expressing CD97  (Fig. 4 B). 
In  conclusion,  the  interaction  between  the  activation- 
regulated CD97 antigen and CD55 implies the existence of 
a  novel  adhesion  pathway  (20)  primarily used  by  primed 
but  not  quiescent  teukocytes.  Remarkably,  anmng  the 
hundreds of known 7-TM receptors CD97 is the first mol- 
ecule  for  which  a  cellular ligand  has  now  been  demon- 
strated (21-23).  It needs to be investigated if this is a com- 
mon  feature  of the  new  group  of 7-TM  receptors  with 
NH2-terminal EGF domains to which CD97  belongs. Al- 
though  the  physiological consequences  of the  interaction 
between  CD97  and  CD55  remain  to  be  determined,  our 
findings  indicate  that  complement  regulation  is  probably 
not  the  exclusive function  of CD55.  Notably,  transgenic 
CD55  is currently being used  to  downmodulate  comple- 
ment  activation by xeno-transplants  (24).  Our  data  imply 
that,  although  the  effect on  complement activation might 
be beneficial for graft survival, attraction of activated leu- 
kocytes to the graft might be an unwanted  (and so far un- 
anticipated) side effect of this approach. 
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